|
gptkbp:accessories
|
experienced during pandemic
|
|
gptkbp:approves
|
gptkb:U._S._Food_and_Drug_Administration
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:clinical_trial
|
gptkb:Brazil
gptkb:South_Africa
gptkb:United_Kingdom
gptkb:United_States
gptkb:Merck_&_Co.
gptkb:Ridgeback_Biotherapeutics
Phase 3
published in medical journals
submitted for review
|
|
gptkbp:collaborations
|
academic institutions
international health organizations
|
|
gptkbp:community_health
|
contributes to pandemic response
aims to reduce burden on healthcare systems
|
|
gptkbp:competitors
|
other COVID-19 treatments
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
|
|
gptkbp:distribution
|
available in multiple countries
|
|
gptkbp:dosage_form
|
gptkb:capsule
|
|
gptkbp:emergency_services
|
granted
|
|
gptkbp:first_described_by
|
gptkb:2021
|
|
gptkbp:funding
|
government and private sectors
|
|
gptkbp:future_prospects
|
exploring new formulations
focused on efficacy against variants
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Molnupiravir
|
|
gptkbp:indication
|
treatment of COVID-19
|
|
gptkbp:interacts_with
|
certain antibiotics
other antiviral medications
|
|
gptkbp:invention
|
gptkb:Merck_&_Co.
|
|
gptkbp:is_effective_against
|
reduces hospitalization and death
|
|
gptkbp:is_studied_in
|
high-risk patients
mild to moderate COVID-19 cases
|
|
gptkbp:marketed_as
|
Lagevrio
|
|
gptkbp:mechanism_of_action
|
inhibits viral replication
|
|
gptkbp:monitoring_adverse_events
|
required by regulatory agencies
|
|
gptkbp:patient_education
|
provided by healthcare providers
|
|
gptkbp:patient_population
|
adults
children (under study)
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:provides_guidance_on
|
included in treatment protocols
|
|
gptkbp:public_awareness
|
promoted by health authorities
|
|
gptkbp:regulatory_compliance
|
varies by country
|
|
gptkbp:research_ongoing
|
long-term effects
combination therapies
variants of concern
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_features
|
monitored post-marketing
|
|
gptkbp:side_effect
|
headache
nausea
diarrhea
|
|
gptkbp:suitable_for
|
severe COVID-19 cases
|
|
gptkbp:supply_chain
|
pharmaceutical distributors
|
|
gptkbp:targets
|
SARS-Co V-2 virus
|
|
gptkbp:type
|
gptkb:immunotherapy
|
|
gptkbp:bfsParent
|
gptkb:Merck's_COVID-19_treatment
|
|
gptkbp:bfsLayer
|
7
|